APICES acknowledged for its remarkable role in BEATcc trial

We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the BEATcc study, an International (EU, USA, APAC) Phase III clinical trial in cervical cancer. This acknowledgement was highlighted during an oral presentation at the ESMO Gynecological Cancers Congress 2025.

APICES has contributed extensively to critical aspects throughout the trial, including start-up, coordination, project management, monitoring, medical monitoring, pharmacovigilance, biostatistics, and medical writing activities.

This acknowledgment is a great motivation for the entire APICES team to continue the commitment we bring to every project we collaborate on. We sincerely thank GEICO-ENGOT and Dra. Ana Oaknin for giving us the opportunity to support the study as CRO and for including us in the oral presentation acknowledgments. We also congratulate them and all investigators and patients on the BEATcc trial progress and results.

The BEATcc clinical trial aims to determine whether combining atezolizumab with bevacizumab plus chemotherapy improves treatment efficacy in patients with metastatic, persistent, or recurrent cervical cancer.

For further information about the BEATcc trial, please visit: BEATcc